Altor BioScience Corporation - Product Pipeline Review - 2012

Global Markets Direct, June 2012, Pages: 51

Altor BioScience Corporation – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Altor BioScience Corporation - Product Pipeline Review - 2012” provides data on the Altor BioScience Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Altor BioScience Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from Altor BioScience Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Altor BioScience Corporation - Brief Altor BioScience Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Altor BioScience Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Altor BioScience Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Altor BioScience Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Altor BioScience Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Altor BioScience Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Altor BioScience Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Altor BioScience Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Altor BioScience Corporation and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Altor BioScience Corporation; Altor BioScience Corporation - Key Therapeutics; Altor BioScience Corporation - Pipeline Overview and Promising Molecules; Altor BioScience Corporation - News; Altor BioScience Corporation - Latest Updates; Altor BioScience Corporation - Pipeline; Altor BioScience Corporation - Discontinued/Dormant Projects

List of Tables
List of Figures
Altor BioScience Corporation Snapshot
Altor BioScience Corporation Overview
Key Information
Key Facts
Altor BioScience Corporation – Research and Development Overview
Key Therapeutic Areas
Altor BioScience Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Altor BioScience Corporation – Pipeline Products Glance
Altor BioScience Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Altor BioScience Corporation – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Altor BioScience Corporation – Drug Profiles
ALT-801
Product Description
Mechanism of Action
R&D Progress
ALT-801 + Cisplatin
Product Description
Mechanism of Action
R&D Progress
ALT-801 + Gemcitabine + Cisplatin
Product Description
Mechanism of Action
R&D Progress
ALT-802
Product Description
Mechanism of Action
R&D Progress
ALT-803
Product Description
Mechanism of Action
R&D Progress
ALT-804
Product Description
Mechanism of Action
R&D Progress
ALT-836
Product Description
Mechanism of Action
R&D Progress
ALT-836 + Gemcitabine
Product Description
Mechanism of Action
R&D Progress
Antiviral TCR-Ck
Product Description
Mechanism of Action
R&D Progress
Antiviral TCR-Ig
Product Description
Mechanism of Action
R&D Progress
IL-15 Antagonist
Product Description
Mechanism of Action
R&D Progress
Altor BioScience Corporation – Pipeline Analysis
Altor BioScience Corporation – Pipeline Products by Therapeutic Class
Altor BioScience Corporation – Pipeline Products By Target
Altor BioScience Corporation – Pipeline Products by Route of Administration
Altor BioScience Corporation – Pipeline Products By Mechanism of Action
Altor BioScience Corporation – Recent Pipeline Updates
Altor BioScience Corporation – Locations And Subsidiaries
Head Office
Altor BioScience Corporation, Recent Developments
Altor BioScience Corporation- Press Release
Apr 30, 2012: Altor And Melanoma Research Alliance To Co-Support Clinical Studies Of ALT-803 To Treat Metastatic Melanoma
Sep 25, 2009: NCI Awards $3 MM SBIR Bridge Grant To Altor BioScience To Advance Clinical Trials For its Targeted Cancer Therapeutic ALT-801
Financial Deals Landscape
Altor BioScience Corporation, Deals Summary
Altor BioScience Corporation, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Altor Bioscience Secures $10.3 Million In Series D Financing
Altor Bioscience Secures $0.3 Million In Venture Financing Round
Altor BioScience Secures $1.2 Million In Series C1 Financing
Altor BioScience Secures $6 Million In Series C1 Financing
Altor BioScience Secures $15 Million In Series C Financing
Altor BioScience Completes Series B Financing
Partnerships
Altor BioScience Enters Into Licensing Agreement With Massachusetts General Hospital
Altor BioScience Enters Into Agreement With Massachusetts General Hospital And Howard Hughes Medical Institute
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Altor BioScience Corporation, Key Information
Altor BioScience Corporation, Key Facts
Altor BioScience Corporation – Pipeline by Indication, 2012
Altor BioScience Corporation – Pipeline by Stage of Development, 2012
Altor BioScience Corporation – Monotherapy Products in Pipeline, 2012
Altor BioScience Corporation – Combination Treatment Modalities in Pipeline, 2012
Altor BioScience Corporation – Phase II, 2012
Altor BioScience Corporation – Phase I, 2012
Altor BioScience Corporation – Pre-Clinical, 2012
Altor BioScience Corporation – Pipeline By Therapeutic Class, 2012
Altor BioScience Corporation - Pipeline By Target, 2012
Altor BioScience Corporation – Pipeline By Route of Administration, 2012
Altor BioScience Corporation – Pipeline Products By Mechanism of Action, 2012
Altor BioScience Corporation – Recent Pipeline Updates, 2012
Altor BioScience Corporation, Deals Summary
Altor Bioscience Secures $10.3 Million In Series D Financing
Altor Bioscience Secures $0.3 Million In Venture Financing Round
Altor BioScience Secures $1.2 Million In Series C1 Financing
Altor BioScience Secures $6 Million In Series C1 Financing
Altor BioScience Secures $15 Million In Series C Financing
Altor BioScience Completes Series B Financing
Altor BioScience Enters Into Licensing Agreement With Massachusetts General Hospital
Altor BioScience Enters Into Agreement With Massachusetts General Hospital And Howard Hughes Medical Institute

List of Figures
Altor BioScience Corporation – Pipeline by Indication, 2012
Altor BioScience Corporation – Pipeline by Stage of Development, 2012
Altor BioScience Corporation – Monotherapy Products in Pipeline, 2012
Altor BioScience Corporation – Combination Treatment Modalities in Pipeline, 2012
Altor BioScience Corporation – Pipeline By Therapeutic Class, 2012
Altor BioScience Corporation - Pipeline By Target, 2012
Altor BioScience Corporation – Pipeline By Route of Administration, 2012
Altor BioScience Corporation - Pipeline Products By Mechanism of Action, 2012

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Altera Corporation
• SYNNEX Corporation
• Bose Corporation
• Avocent Corporation - SWOT Analysis
• Scientific Games Corporation - Company Analysis
• Black & Decker Corporation - SWOT Analysis
• SanDisk Corporation
• Nortel Networks Corporation
• Ixia - Company Analysis